Sedentary Behavior Interrupted: A Trial of Acute Effects on Biomarkers of Healthy Aging
1 other identifier
interventional
78
1 country
1
Brief Summary
This protocol "Sedentary Behavior Interrupted: A randomized crossover trial of acute effects on biomarkers of healthy aging in the laboratory (Project 1)" is part of a National Institutes of Aging Program Grant called "Sedentary Time \& Aging Mortality and Physical Function (STAR). The overall purpose of the STAR program to is to better understand how to interrupt sitting time and the consequences for healthy aging in postmenopausal women. This protocol (also referred to Project 1 of the STAR program) is a 3-condition randomized crossover clinical trial of up to 86 postmenopausal women to test whether different interruptions to prolonged sitting improve metabolism.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2018
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 26, 2018
CompletedFirst Posted
Study publicly available on registry
April 27, 2018
CompletedStudy Start
First participant enrolled
May 8, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedJune 14, 2024
June 1, 2024
6 years
March 26, 2018
June 13, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Postprandial glucose
To investigate the acute effect of sitting interruption modalities on postprandial glucose compared to prolonged sitting.
5 hours
Insulin
To investigate the acute effect of sitting interruption modalities on insulin concentrations compared to prolonged sitting.
5 hours
Secondary Outcomes (2)
Flow mediated dilation
5 hours
Blood pressure
5 hours
Study Arms (3)
Control Condition (Protocol A)
NO INTERVENTIONFollowing a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
Frequent Sit-to-Stands (Protocol B)
EXPERIMENTALFollowing a 1-hour sitting run-in period, participants will sit for a 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period and a mid-point bathroom break.
Stand More (Protocol C)
EXPERIMENTALFollowing a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 8-minute standing breaks, 1 per hour, and a mid-point bathroom break.
Interventions
Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 8-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
Eligibility Criteria
You may qualify if:
- female
- years of age and above
- any ethnicity or race
- screened to sit for 8 or more hours per day, perform less than 60 sit-to-stand transitions per day \& engage in less than 20 minutes of moderate-to-vigorous physical activity (MVPA) per day
- BMI 25 - 45 kg/m2
- ambulatory
- medically stable without any health conditions that would inhibit standing or PA;
- able to give informed consent \& comply with study protocols;
- able to read, communicate, and write fluently in English;
- able to travel to study visits;
- no menstruation for at least one year;
- not participating or not planning to participate in a physical activity or weight loss program or research study.
You may not qualify if:
- Mental state that would preclude complete understanding of the protocol or compliance;
- type 1 diabetes;
- type 2 diabetes using insulin or with poor glycemic control (greater than 10% for all participants);
- poorly controlled hypertension (Systolic Blood Pressure ≥165 or Diastolic Blood Pressure ≥100);
- chronic illness that may be associated with weight change (HIV/AIDS, active cancer, or uncontrolled thyroid disease),
- anemia (hemoglobin ≤11g/dL);
- personal or first-degree relative history of venous thrombosis;
- weight instability in past 3 months (no more than 5% up or down);
- regular use of vasodilator medication and high risk of stroke and/or heart attack (i.e., history of multiple hospitalizations (\>2X) in the last 6 months), congestive heart failure, atrial fibrillation, and/or stroke;
- regular use of immunosuppressant or corticosteroid medication;
- blood donation less than 56 days prior to screening visit,
- smoking cigarettes or smoking or ingesting anything, and other use of tobacco products including e-cigarettes.
- diagnosis of orthostatic hypotension
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UC San Diego
La Jolla, California, 92093, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
March 26, 2018
First Posted
April 27, 2018
Study Start
May 8, 2018
Primary Completion
April 30, 2024
Study Completion
December 31, 2024
Last Updated
June 14, 2024
Record last verified: 2024-06
Data Sharing
- IPD Sharing
- Will share